Home › Calculator › LLY Dividend Calculator 2026
LLY Dividend DRIP Calculator 2026
0.53% YieldHealthcareEli Lilly and Company · NYSE
Price: $1,254.77 · Annual div: $6.69/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Calculator settings
Portfolio growth: DRIP vs No DRIP
Annual dividend income growth
💡 What-if scenarios
Click to apply scenario to the calculator
🎯 When LLY pays your bills
Year your monthly dividend income covers each expense (based on current settings)
Share your LLY snowball 📈
$10,000 in LLY → $10.80M in 10 years · $4,772.71/month
About Eli Lilly and Company (LLY) — Dividend Analysis 2026
Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offerings include a comprehensive suite of diabetes medications. This encompasses various insulin formulations like Basaglar, the Humalog family (e.g., Mix 75/25, U-100, U-200, Mix 50/50), insulin lispro products (including protamine and mix 75/25), and the Humulin line (e.g., 70/30, N, R, U-500). Furthermore, Eli Lilly provides specialized treatments for type 2 diabetes, such as Jardiance, Trajenta, and Trulicity. In oncology, Eli Lilly offers a robust portfolio targeting various cancers. These include Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza, indicated for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal and various head and neck cancers; Retevmo, used in metastatic NSCLC, medullary thyroid, and other thyroid cancers; Tyvyt for relapsed or refractory classic Hodgkin's lymphoma and non-squamous NSCLC; and Verzenio, prescribed for HR+, HER2- metastatic breast cancer, node-positive, and early breast cancer. For autoimmune and inflammatory conditions, the company markets Olumiant for rheumatoid arthritis, and Taltz, which addresses plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Addressing neurological and pain management needs, Eli Lilly provides Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain. Emgality is available for migraine prevention and episodic cluster headaches, while Zyprexa treats schizophrenia, bipolar I disorder, and aids in bipolar maintenance. Other significant products include Bamlanivimab and etesevimab, along with Bebtelovimab, both developed for COVID-19. Cialis is offered for erectile dysfunction and benign prostatic hyperplasia, and Forteo is available for osteoporosis. Eli Lilly actively engages in strategic collaborations with numerous partners, including Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Established in 1876, Eli Lilly and Company maintains its corporate headquarters in Indianapolis, Indiana.
Compare LLY with similar stocks
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
Get Your Full LLY DRIP Report by Email
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open LLY position with:
🌍 LLY Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold LLY.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 0.53% | -2.27% | $53 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 0.45% | -2.35% | $45 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 0.42% | -2.38% | $42 / yr |
| 🇬🇧 UK ISA | 0% | 0.53% | -2.27% | $53 / yr |
| 🇬🇧 UK Taxable | 8.75% | 0.48% | -2.32% | $48 / yr |
| 🇨🇦 TFSA | 0% | 0.53% | -2.27% | $53 / yr |
| 🇨🇦 CA Taxable | 25% | 0.40% | -2.40% | $40 / yr |
| 🇦🇺 Super (pension) | 15% | 0.45% | -2.35% | $45 / yr |
| 🇦🇺 AU Taxable | 30% | 0.37% | -2.43% | $37 / yr |
| 🇩🇪 DE Taxable | 26.375% | 0.39% | -2.41% | $39 / yr |
| 🇫🇷 FR Taxable | 30% | 0.37% | -2.43% | $37 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 LLY Income Goal & Break-Even
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $6.69/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 LLY Dividend Payment Schedule
LLY pays quarterly — 4 times per year. Next ex-div: TBD.
📊 LLY vs Healthcare Benchmarks
How LLY compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for LLY sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ LLY Insider Activity
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| A-Award | 2026-08-17 | 4.191 | $1183.16 | $5.0K | ||
| A-Award | 2026-08-17 | 13.453 | $1183.16 | $15.9K | ||
| A-Award | 2026-08-17 | 8.382 | $1183.16 | $9.9K | ||
| A-Award | 2026-08-17 | 10.495 | $1183.16 | $12.4K | ||
| Sale | 2026-08-17 | 6,500 | $1175.10 | $7.64M | ||
| Sale | 2026-08-10 | 2,000 | $1185.01 | $2.37M | ||
| Sale | 2026-08-07 | 5,000 | $1190.00 | $5.95M | ||
| M-Exempt | 2026-08-01 | 981 | — | — | ||
| F-InKind | 2026-08-01 | 438.707 | $1148.84 | $504.0K | ||
| M-Exempt | 2026-08-01 | 981 | — | — |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Analyst Price Target
Wall Street consensusAnalyst consensus price target via FMP. Not a guarantee of future performance. Past analyst accuracy varies.
Financial Health Scores
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Geographic Revenue Breakdown
Where LLY earns its moneyRevenue breakdown from latest annual report via FMP. Percentages may not sum to 100% due to rounding.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the LLY dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Eli Lilly and Company (LLY) is currently trading at $1,254.77, trading near its 52-week high. The current dividend yield is 0.53% based on an annual payout of $6.69 per share.
LLY (Eli Lilly and Company) — 0.53% Dividend Yield Analysis
Eli Lilly and Company (LLY) is a healthcare stock currently trading at $1254.77 with a dividend yield of 0.53%. The company pays an annual dividend of $6.69 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings. Over the past 5 years, LLY has grown its dividend at a compound annual rate of 100.0%.
- Dividend payments are not guaranteed and can be reduced or suspended at any time.
Auto-generated from live market data. For educational purposes only — not financial advice.